Sofiva GenomicsLtd Valuation

Q: What is the Fair Price of 6615 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6615 (NT$45) is trading above our estimate of [[fair value]] (NT$3.12)

Is 6615 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6615 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6615 (NT$45) is trading above our estimate of fair value (NT$3.12)

Significantly Below Fair Value: 6615 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6615?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 6615. This is calculated by dividing 6615's market cap by their current preferred multiple.
What is 6615's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	NT$961.31m

6615 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	86.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6615's PE Ratio compare to its peers?

The above table shows the PE ratio for 6615 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	58.3x
6518 Concord Medical	18.6x	n/a	NT$796.7m
6637 Medical Imaging	17.6x	n/a	NT$2.1b
6879 TCI GENE	181.3x	n/a	NT$2.1b
6744 Feng Chi Biotech	15.5x	n/a	NT$352.7m
6615 Sofiva GenomicsLtd	83.4x	n/a	NT$961.3m

Price-To-Earnings vs Peers: 6615 is expensive based on its Price-To-Earnings Ratio (83.4x) compared to the peer average (58.3x).

Price to Earnings Ratio vs Industry

How does 6615's PE Ratio compare vs other companies in the Asian Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.7%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 6615 is expensive based on its Price-To-Earnings Ratio (83.4x) compared to the Asian Healthcare industry average (21.8x).

Price to Earnings Ratio vs Fair Ratio

What is 6615's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6615 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	83.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6615's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.